KLYG logo

Kelyniam Global, Inc. (KLYG) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

KLYG, $ (piyasa değeri 0) fiyatla Healthcare işi olan Kelyniam Global, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 51/100 puan alıyor.

Son analiz: 17 Mar 2026
51/100 AI Puanı

Kelyniam Global, Inc. (KLYG) Sağlık ve Boru Hattı Genel Bakışı

CEORoss Bjella
Çalışanlar9
MerkezCollinsville, US
Halka Arz Yılı2008
SektörHealthcare

Kelyniam Global, Inc. focuses on custom cranial and craniofacial prosthetics, utilizing advanced medical-grade polymers and CAD/CAM technology. Serving health systems and surgeons, the company addresses reconstructive needs within a niche market. Kelyniam operates in a competitive medical device landscape, balancing innovation with regulatory demands.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

Kelyniam Global, Inc. presents a focused investment opportunity within the niche market of custom cranial and craniofacial prosthetics. The company's reliance on advanced CAD/CAM technology and medical-grade polymers allows for patient-specific solutions, potentially driving demand and revenue growth. A gross margin of 35.7% indicates some pricing power, but a negative profit margin of -52.2% highlights profitability challenges. Future growth hinges on expanding market reach, securing regulatory approvals for new products, and managing operational costs effectively. Investors should monitor the company's ability to scale production, maintain quality standards, and navigate the competitive landscape of medical device manufacturing. The company's beta of 0.53 suggests lower volatility compared to the broader market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Kelyniam Global, Inc. operates with a small team of 9 employees, indicating a lean operational structure.
  • The company's gross margin stands at 35.7%, reflecting its ability to generate revenue above direct production costs.
  • Kelyniam Global, Inc. has a negative profit margin of -52.2%, signaling challenges in achieving overall profitability.
  • The company's beta of 0.53 suggests lower volatility compared to the broader market, potentially appealing to risk-averse investors.
  • Kelyniam Global, Inc. serves health systems, hospitals, and surgeons, demonstrating a direct-to-customer approach.

Rakipler & Benzerleri

Güçlü Yönler

  • Customization capabilities for patient-specific needs.
  • Use of advanced CAD/CAM technology.
  • Direct sales to health systems and surgeons.
  • Specialized focus on cranial and craniofacial prosthetics.

Zayıflıklar

  • Small company size limits scalability.
  • Negative profit margin indicates financial challenges.
  • Limited product portfolio compared to larger competitors.
  • Reliance on a niche market.

Katalizörler

  • Upcoming: Potential FDA approval for new custom prosthetic designs could expand market reach.
  • Ongoing: Strategic partnerships with hospitals and surgical centers to increase product adoption.
  • Ongoing: Expansion of geographic reach into new domestic and international markets.
  • Ongoing: Development of new materials and manufacturing processes to improve product performance.
  • Ongoing: Increasing demand for personalized medicine and custom implants.

Riskler

  • Potential: Competition from larger medical device manufacturers with greater resources.
  • Potential: Regulatory hurdles and compliance requirements for medical devices.
  • Potential: Economic downturn impacting healthcare spending and demand for elective procedures.
  • Ongoing: Negative profit margin indicates financial instability.
  • Ongoing: Limited trading volume and price volatility due to OTC listing.

Büyüme Fırsatları

  • Expanding Product Portfolio: Kelyniam can expand its product portfolio to include a wider range of custom prosthetics and implants. This could involve developing solutions for other areas of the body or creating specialized products for specific surgical procedures. The market for custom implants is growing, driven by the increasing demand for personalized medicine. By expanding its product offerings, Kelyniam can capture a larger share of this market and increase its revenue streams. Timeline: 2-3 years.
  • Geographic Expansion: Kelyniam can expand its geographic reach by targeting new markets both domestically and internationally. This could involve establishing partnerships with distributors or opening new sales offices in key regions. The global market for medical devices is growing rapidly, particularly in emerging economies. By expanding its geographic presence, Kelyniam can tap into new sources of demand and diversify its revenue base. Timeline: 3-5 years.
  • Strategic Partnerships: Kelyniam can form strategic partnerships with hospitals, surgical centers, and other healthcare providers. These partnerships can provide Kelyniam with access to new customers, distribution channels, and research and development resources. By collaborating with other players in the healthcare industry, Kelyniam can strengthen its market position and accelerate its growth. Timeline: 1-2 years.
  • Technological Innovation: Kelyniam can invest in research and development to develop new and innovative products and technologies. This could involve exploring new materials, manufacturing processes, or software solutions. The medical device industry is constantly evolving, and companies that can innovate and adapt to new technologies will be best positioned for success. By investing in R&D, Kelyniam can maintain its competitive edge and drive future growth. Timeline: Ongoing.
  • Regulatory Approvals: Securing regulatory approvals for new products and expanding indications for existing products can significantly drive growth. Navigating the regulatory landscape, particularly with the FDA, requires a dedicated strategy and resources. Successful approvals can open up new market segments and increase the adoption of Kelyniam's products among healthcare providers. Timeline: Ongoing.

Fırsatlar

  • Expanding product portfolio to address broader reconstructive needs.
  • Geographic expansion into new markets.
  • Strategic partnerships with hospitals and surgical centers.
  • Technological innovation in materials and manufacturing processes.

Tehditler

  • Competition from larger medical device manufacturers.
  • Regulatory hurdles and compliance requirements.
  • Economic downturn impacting healthcare spending.
  • Technological obsolescence.

Rekabet Avantajları

  • Customization capabilities provide a competitive edge.
  • Proprietary CAD/CAM design and manufacturing processes.
  • Direct relationships with health systems and surgeons.

KLYG Hakkında

Kelyniam Global, Inc., established in 2005 and based in Collinsville, Connecticut, is a medical device manufacturing company specializing in custom cranial and craniofacial prosthetics. Originally incorporated as Ketner Global Investments, Inc., the company rebranded to Kelyniam Global, Inc. in December 2007 to reflect its focus on medical device solutions. Kelyniam utilizes computer-aided design (CAD) and computer-aided manufacturing (CAM) to produce advanced medical-grade polymer prosthetics tailored to individual patient needs. Their product line includes custom cranial implants and craniofacial fixation screws, essential for patients undergoing reconstructive surgery due to trauma, tumors, or congenital defects. Kelyniam distributes its products directly to health systems, hospitals, and surgeons, as well as through sales representatives, serving both domestic and international markets. The company's commitment to precision and patient-specific solutions positions it within the competitive medical device industry, emphasizing innovation and quality in the reconstructive surgery space. Kelyniam aims to provide surgeons with the tools necessary to achieve optimal patient outcomes through customized medical devices.

Ne Yaparlar

  • Designs custom cranial and craniofacial prosthetics using CAD.
  • Manufactures prosthetics using advanced medical-grade polymers.
  • Distributes custom cranial implants and craniofacial fixation screws.
  • Serves health systems and hospitals directly.
  • Provides solutions for reconstructive surgery needs.
  • Utilizes computer-aided manufacturing (CAM) techniques.

İş Modeli

  • Designs and manufactures custom prosthetics based on specific patient requirements.
  • Sells products directly to health systems, hospitals, and surgeons.
  • Generates revenue through the sale of custom cranial implants and craniofacial fixation screws.

Sektör Bağlamı

Kelyniam Global, Inc. operates within the medical device industry, specifically focusing on custom prosthetics for cranial and craniofacial reconstruction. The global medical device market is projected to reach $600 billion by 2026, driven by an aging population, technological advancements, and increasing demand for minimally invasive procedures. The competitive landscape includes larger medical device manufacturers and specialized firms offering similar custom solutions. Kelyniam's success depends on its ability to differentiate through innovation, quality, and customer service within this growing but competitive market.

Kilit Müşteriler

  • Health systems requiring custom prosthetic solutions.
  • Hospitals performing reconstructive surgeries.
  • Surgeons specializing in cranial and craniofacial procedures.
AI Güveni: 79% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

Kelyniam Global, Inc. (KLYG) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

KLYG için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

KLYG için Wall Street fiyat hedefi analizi.

MoonshotScore

51/100

Bu puan ne anlama geliyor?

MoonshotScore, KLYG'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Ross Bjella

Unknown

Information about Ross Bjella's background is not available in the provided data. Further research is needed to determine his career history, education, and previous roles.

Sicil: Information about Ross Bjella's track record is not available in the provided data. Further research is needed to determine his key achievements, strategic decisions, and company milestones under his leadership.

KLYG OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that Kelyniam Global, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Unlike companies listed on major exchanges like NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may have a higher risk profile.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity assessment for Kelyniam Global, Inc. on the OTC market is challenging due to limited trading volume and potential wide bid-ask spreads. This can make it difficult for investors to buy or sell shares quickly and at a desired price. The lack of consistent trading activity may result in price volatility and increased transaction costs. Investors should exercise caution and be aware of the potential for illiquidity when trading KLYG on the OTC market.
OTC Risk Faktörleri:
  • Limited financial disclosure increases investment risk.
  • Low trading volume can lead to price volatility.
  • Potential for wider bid-ask spreads increases transaction costs.
  • Higher risk of fraud or manipulation compared to listed exchanges.
  • OTC Other tier indicates the company may not meet minimum financial standards.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and SEC filings (if any).
  • Assess the company's management team and their experience.
  • Research the company's products and services and their market potential.
  • Evaluate the company's competitive landscape and its position within the industry.
  • Check for any legal or regulatory issues involving the company.
  • Monitor the company's trading volume and price volatility.
  • Consult with a financial advisor before investing.
Meşruiyet Sinyalleri:
  • Company has been in operation since 2005.
  • Focus on a specific niche market (cranial and craniofacial prosthetics).
  • Direct sales to health systems and surgeons suggest established relationships.
  • Use of CAD/CAM technology indicates a commitment to innovation.
  • Company headquarters located in Collinsville, Connecticut.

Yatırımcılar Kelyniam Global, Inc. (KLYG) Hakkında Ne Soruyor

KLYG için değerlendirilmesi gereken temel faktörler nelerdir?

Kelyniam Global, Inc. (KLYG) şu anda yapay zeka skoru 51/100, orta puanı gösteriyor. Temel güçlü yan: Customization capabilities for patient-specific needs.. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device manufacturers with greater resources.. Bu bir finansal tavsiye değildir.

KLYG MoonshotScore'u nedir?

KLYG şu anda MoonshotScore'da 51/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

KLYG verileri ne sıklıkla güncellenir?

KLYG fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler KLYG hakkında ne diyor?

KLYG için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

KLYG'a yatırım yapmanın riskleri nelerdir?

KLYG için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device manufacturers with greater resources.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

KLYG'ın P/E oranı nedir?

KLYG için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için KLYG'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

KLYG aşırı değerli mi, yoksa düşük değerli mi?

Kelyniam Global, Inc. (KLYG)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

KLYG'ın temettü verimi nedir?

Kelyniam Global, Inc. (KLYG) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • Limited financial information available for Kelyniam Global, Inc.
  • OTC market investments carry higher risk.
  • AI analysis pending for KLYG stock.
Veri Kaynakları

Popüler Hisseler